Shots:

• Synaffix is eligible to receive up front & milestones with a total deal value of $1B & is also eligible to receive royalties under the previous collaboration b/w Synaffix & Mersana as reported in 2019
• The collaboration will leverage Synaffix’s GlycoConnect site-specific ADC bioconjugation technology to produce ADC products. Mersana gets the rights for specific ADC targets & get non-exclusive access to use GlycoConnect site-specific ADC bioconjugation technology for 6 additional ADC targets
• Mersana will lead the research, development, manufacturing & commercialization of ADC products & is currently developing two programs XMT-1592 & XMT-1660, based on ADC bioconjugation technology

Ref: PR Newswire | Image: Synaffix